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Second Autologous Stem Cell Transplant- an Effective
Therapy for Relapsed Multiple Myeloma
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Background: Therapeutic options for patients with Multiple
myeloma (MM) whose disease has relapsed after a prior
autologous stem cell transplant (SCT) include an expanding
armamentarium of novel agents, often combined with
traditional chemotherapy, or a second SCT, with no clear
standard of care.
Methods: We retrospectively analyzed the outcomes of pa-
tients who underwent salvage melphalan-based SCT for
relapsed MM at Memorial Sloan-Kettering Cancer Center.
Results: Between 1995 and 2012, 75 patients with MM
received an initial SCTand then second autograft for relapsed
disease at our center. Conditioning was with melphalan
200mg/m2 (N¼43), 180mg/m2 (N¼1), 140mg/m2 (N¼22),
100mg/m2 (N¼9). The median age at 2nd SCT was 59 years
(range 36-75) and 58% (N¼35) were male. Of those with
available data, 35% had high risk cytogenetics (including t
(4;14), +1q, p53 loss or del 13q by karyotype) at the time of
second SCT. Median interval between ﬁrst and salvage SCT
was 38 months (range 7 -113). Of 71 evaluable patients, 73%
had chemotherapy sensitive disease prior to salvage SCT and
27% were chemoresistant. Response was assessed at 2-3 mos
post-SCT and 84% of evaluable patients achieved >¼ partial
response (PR),10% had stable disease (SD), and 7% progressed
despite salvage SCT. Following salvage SCT, 37 patients
received maintenance therapy and 15 went on to allogeneic
SCT. The median PFS following second autograft was 10.1
mos (95% CI: 7.9-13.6); the median OS was 24 mos (95% CI:
19.5e 50.5). Patients with chemosensitive relapse had better
progression free survival (HR-0.51, CI: 0.22-0.77, P ¼ .005)
and overall survival (HR¼0.37, CI- 0.19-0.70, P ¼ .002) than
patients with resistant relapse. Those with high-risk cyto-
genetics at the time of second SCT had higher risk of death
(HR 2.12, 95% CI: 1.03- 4.38, P ¼ .04) compared to patients
with standard risk cytogenetics.
Conclusions: Salvage SCT is an effective strategy for relapsed
MM with chemosensitive disease and results in comparablePFS and OS to other salvage strategies. With the FDA approval
of multiple novel effective therapies, more relapsed patients
will likely achieve measurable responses and should be
evaluated for second stem cell transplant. Incorporation of
novel conditioning regimens and/or effective maintenance
strategies may further improve outcomes with this approach125
Cytomegalovirus Reactivation Following Autologous
Peripheral Blood Stem Cell Transplantation for
Lymphoma and Multiple Myeloma, Single Center
Experience
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Introduction: There are few s studies about cytomegalovirus
reactivation after autologous peripheral blood stem cell
transplantation (PBSCT).
Methods: At our center we retrospectively reviewed the ﬁles
for all adult patients with diagnosis of lymphoma or multiple
myeloma (MM), who underwent autologous PBSCT between
2007-2012.
All these patients were on acyclovir or valacyclovir pro-
phylaxis, CMV pp65 antigenemia testing was performed
weekly till day 40 post transplant, and preemptive therapy
was started if the antigenemia test was positive in 5 cells, or
more than once positive<5 cells plus unexplained low
counts, or elevated liver enzymes.
Results: During the six years period, 210 patients underwent
autologous transplant (lymphoma 55%, MM45%).97.6% of the
patients were CMV IgG positive before transplant.
The rate of CMV reactivation requiring preemptive ther-
apy as per the criteria above was 17.6%, with median time for
reactivation of 31 days.
There was no difference in the rate of reactivation be-
tween lymphoma and MM, and lymphoma.
Ganciclovir was used as ﬁrst line therapy in 70.3%, Val-
ganciclovir in 24.3% and Foscarnet in 5.4%. The median
duration of induction therapy was 8 days and for mainte-
nance was 10 days.
None of our patients developed CMV disease in any organ,
and the main toxicity was cytopenia with the Ganciclovir/
Vaganciclovir, and renal impairment with electrolytes
imbalance with Foscarnet.
At the time of the study 76% of the group were alive, with
55% were free of progression.
Conclusion: CMV reactivation rate is low after autologous
PBSCT, no need for CMV monitoring beyond 40 days, and
with preemptive therapy you can eradicate CMV infection.126
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Table
Factors Affecting the Post-transplant Progression Free Survival
PFS (months)
mean SD
95% CI P
Sex
Female
Male
26.1  2.6
20.3  2.2
21.0-31.2
16.0-24.5
.135
Subtype
Light chain
Others
30.6  3.0
20.3  1.9
24.7-36.5
16.5-24.1
.008
International Staging System 27.2  2.8 21.7-32.7 .047
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Introduction: High dose therapy followed by autologous
hematopoietic stem cell transplantation (ASCT) has an
established role in the treatment of patients with multiple
myeloma (MM). The CR rate, an indicator for progression-
free and overall survival (PFS; OS) observed after the most
commonly used conditioning regimen Mel200 (Melphalan
200mg/m2) is between 10-35%. The objective of our trial is to
assess whether conditioning with a combination of PK-
directed Busulfan (Bu), Mel and Bortezomib (Btz) is safe and
can improve CR rates in patients with MM.
Methods: Patients aged 18-72 with MM, who had received
less than one year of prior myeloma-directed therapy and
were eligible for ASCT were assigned to receive PK-directed
i.v. Bu, i.v. Mel and i.v. Btz as per Fig. 1. Subsequent con-
solidative or maintenance therapy was left to investigator’s
choice. Primary outcome was CR rate assessed on D +100
post ASCT as per IMWG criteria. Secondary outcomes are
overall response rate (ORR), toxicities, PFS and OS. The trial is
registered at clinicaltrials.gov (NCT01605032).
Results: To date, 18 patients have been treated (median age
61 (range 44-70), 61% male, 17% with ISS stage 3; median
number of prior regimens 1 (range 1-3); prior bortezomib
94%). For the 12 evaluable patients the median days to ANC
>/¼0.5 x 109/L and platelet count >/¼30 x 109/L were 11
(range 10-13) and 17 (11-29), respectively. Themost common
non-hematological toxicities (100%) were alopecia, oral
mucositis (62% G3), dysphagia (85% G3), as well as electrolyte
abnormalities (62% G3). Other common toxicities were
nausea (92%, all G1/2), diarrhea (84% G1/2, 15% G3), while
84% of patients developed fully reversible transaminitis (15%
G3). Less common G3 toxicities included delirium (8%), co-
litis (8%), skin infection (15%; zoster & skin abscess, 1 each),
other infections (31%), and engraftment syndrome (8%). No
patient developed sinusoidal obstruction syndrome of the
liver. Response assessment was available for 11 patients: 1
achieved a stringent CR (9.1%), 5 VGPR (45.5%), and 5 PR
(45.5%), resulting in a 100% ORR. After a median follow up of
5.2 months (range 1-18) all patients are alive and no patient
has relapsed. The trial is ongoing.
Conclusion: PK directed i.v. Bu in combination with Mel and
Btz (BuMelBtz) is an effective and safe conditioning regimen
for patients with MM. Further evaluation is warranted.Fig. 1. Treatment Schema
Following a Busulfan (Bu) test dose (0.8mg/kg) prior to the ﬁrst treatment
dose, intravenous (i.v.) Bu is given 4 times daily as 3-hour infusion from day
(D) -6 to -3 to target a total AUC of 20,000 uMxmin (PK-directed Busulan); i.v.
Melphalan (Mel; 140mg/m2) is given on D-2, and i.v. Bortezomib (BTZ; 1.4mg/
m2) on D-6, -4, +1 and +4.127
Chemosensitivity to Induction or High Dose Therapy, Pre/
Post Transplant PET Negativity and Absence of Minimal
Residual Disease within Mobilized Stem Cell Graft Predict
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Despite the improvements in response rates in multiple
myeloma during the last decade, relapses still remain as a
problem. Aim of this study was to evaluate the factors
associated with response and the length of progression free
survival (PFS) following autologous hematopoietic cell
transplantation (ASCT). Out of 113 consecutive patients with
newly diagnosed MM, 43 % and 19% achieved Post-ASCT
complete remission (CR) or very good partial remission
(VGPR) respectively. Post-ASCT response status was signiﬁ-
cantly associated with female sex, light chain myeloma, b-2
microglobulin (3.5mg/L) and pre-ASCT response status.
Multiparameter ﬂow cytometry detected abnormal plasma
cells (APC) in the harvests of 9.7% of patients. Higher pro-
portion of patients who had contaminated harvests were at
<VGPR status duringmobilization compared to patients who
did not have contamination (73% vs 53%; p¼.088). Presence
of APC in the harvests compared to those lacking APC was
signiﬁcantly associated with progression at 12 months after
ASCT (75% vs 36%; p¼.039). The median PFS was 13 (2-45)
months after a median follow-up of 33 (7-148) months.ISS1
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24.2  2.9
15.9  2.7
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10.7-21.1
Cytogenetics
del13q negative
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24.0  3.1
14.5  2.5
18.1-30.0
9.4-19.5
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b 2 microglobulin, mg/L
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>3.5
25.7  2.7
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20.5-30.9
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Post-transplant PET
Negative
Positive
30.1  3.2
17.8  2.6
23.9-36.3
12.7-22.8
.008
APC in harvests
Absent
Present
24.0  1.9
14.4  3.3
20.4-27.7
8.0-20.8
.206
Pre-transplant response
<PR
PR
VGPR
CR
14.8  3.8
19.9  2.5
28.2  4.3
28.4  2.8
7.3-22.2
15.0-24.8
19.8-36.7
22.8-33.9
.021
Post-transplant response
<PR
PR
VGPR
CR
3.2  1.2
17.1  2.8
30.9  3.7
26.9  1.8
0.85-5.55
11.6-22.6
23.7-38.0
19.8-26.7
.001
